Glaukos today raised the proposed price range on its pending initial public offering, saying it will offer 6 million shares at $16 to $17 apiece, which at the midpoint would fetch $99.0 million. In May, Laguna Hills, Calif.-based Glaukos initially said the offering could gross as much as $86.2 million. Earlier this month the company said it planned […]
Glaukos yesterday registered for an initial public offering worth as much as $86.2 million.
The iStent made by Laguna Hills, Calif.-based Glaukos was the 1st micro-invasive glaucoma surgery device to hit the U.S. market. It’s a tiny titanium stent designed to alleviate the intra-ocular pressure caused by glaucoma.
Medical device companies pulled in more than $255 million from investors in 29 deals during January, according to data provided to MassDevice.com by CB Insights Inc.
The deals ranged widely in size, from a $25,000 seed round investment for Elyira, Ohio-based Guided Interventions and its passive coronary artery blockage sensing technology to a $43 million Series D round for EndoChoice and its endoscopes.
The FDA said it gave pre-market approval to Glaukos Corp. to market its iStent device in the U.S. for cataract surgeries.